Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $73.00 Price Target

Aerie Pharmaceuticals (NASDAQ:AERI) has been assigned a $73.00 target price by equities research analysts at Canaccord Genuity in a research note issued on Monday. The firm presently has a “buy” rating on the stock. Canaccord Genuity’s target price would suggest a potential upside of 25.32% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. Guggenheim started coverage on Aerie Pharmaceuticals in a research report on Monday, October 23rd. They issued a “buy” rating and a $80.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $76.00 price objective (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. Mizuho reiterated a “buy” rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a research report on Monday, October 16th. JMP Securities set a $68.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $62.00 price objective on shares of Aerie Pharmaceuticals in a research report on Wednesday, October 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $72.00.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded down $0.05 on Monday, reaching $58.25. The company’s stock had a trading volume of 1,120,233 shares, compared to its average volume of 508,423. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 52-week low of $35.50 and a 52-week high of $66.60.

Several hedge funds have recently added to or reduced their stakes in AERI. California Public Employees Retirement System bought a new stake in shares of Aerie Pharmaceuticals during the first quarter worth $231,000. Aperio Group LLC raised its position in shares of Aerie Pharmaceuticals by 4.7% during the second quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock worth $258,000 after acquiring an additional 219 shares during the last quarter. Sei Investments Co. raised its position in shares of Aerie Pharmaceuticals by 53,632.1% during the second quarter. Sei Investments Co. now owns 15,045 shares of the company’s stock worth $790,000 after acquiring an additional 15,017 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Aerie Pharmaceuticals by 1.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 138,289 shares of the company’s stock worth $7,268,000 after acquiring an additional 2,183 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Aerie Pharmaceuticals by 3.7% during the second quarter. Rhumbline Advisers now owns 34,913 shares of the company’s stock worth $1,835,000 after acquiring an additional 1,237 shares during the last quarter.

WARNING: “Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $73.00 Price Target” was originally posted by American Banking and Market News and is the sole property of of American Banking and Market News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/19/canaccord-genuity-analysts-give-aerie-pharmaceuticals-aeri-a-73-00-price-target.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).